<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140125</url>
  </required_header>
  <id_info>
    <org_study_id>2408-CL-9101</org_study_id>
    <nct_id>NCT02140125</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects</brief_title>
  <official_title>Phase I Study of ASP2408 -Subcutaneous Single-dose, Placebo-controlled Study in Non-elderly Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of&#xD;
      single subcutaneous dose of ASP2408 in non-elderly healthy adult male subjects. The&#xD;
      pharmacodynamics of ASP2408 is also being evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study will be conducted as a double-blind, placebo-controlled, single ascending&#xD;
      subcutaneous dose study. As shown in the table below, the study will be conducted using 3&#xD;
      cohorts, to which a total of 24 subjects will be randomly assigned (18 subjects receiving&#xD;
      ASP2408 and 6 subjects receiving placebo). Each cohort will consist of 8 subjects, who will&#xD;
      be randomly assigned to either the ASP2408 group or the placebo group at the ratio of 3 to 1.&#xD;
&#xD;
      Each subject will need to be hospitalized until Day 8 (start date of study drug&#xD;
      administration will be regarded as Day 1) and will be observed until Day 90. The investigator&#xD;
      or subinvestigator will carefully observe each subject for any sign or symptom of adverse&#xD;
      events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, lab tests, and 12-lead ECG</measure>
    <time_frame>Up to 90 days after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of serum ASP2408</measure>
    <time_frame>On day-1, day-2, day-3, day-4, day-5, day-6, day-7, day-8, day-9, day-11, day-13, day-15, day-22, day-29 day-43, day-60 and day-90</time_frame>
    <description>The pharmacokinetic analysis employed non-compartmental methods using serum concentrations of ASP2408. The following pharmacokinetic parameters were estimated: AUCinf, AUClast, Cmax, CL/F, tmax, t1/2, and Vz/F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD80/CD86 receptor occupancy</measure>
    <time_frame>On day-1, day-2, day-3, day-5, day-8, day 15, day-22, day-29 and day-90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lymphocyte count</measure>
    <time_frame>On day-1, day-2, day-3, day-5, day-8, day 15, day-22, day-29 and day-90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood lymphocyte subset</measure>
    <time_frame>On day-1, day-2, day-3, day-5, day-8, day 15, day-22, day-29 and day-90</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP2408</condition>
  <arm_group>
    <arm_group_label>ASP2408 low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2408 middle dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2408 high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2408</intervention_name>
    <description>subcutaneous administration</description>
    <arm_group_label>ASP2408 high dose group</arm_group_label>
    <arm_group_label>ASP2408 low dose group</arm_group_label>
    <arm_group_label>ASP2408 middle dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous administration</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI (at screening): â‰¥ 17.6 kg/m2, &lt; 26.4 kg/m2&#xD;
&#xD;
          -  Healthy, as judged by the investigator or subinvestigator based on the results of&#xD;
             medical examination (subjective symptoms and objective findings) and all tests&#xD;
             obtained at screening and during the period from hospitalization (Day -2) to&#xD;
             immediately before study drug administration&#xD;
&#xD;
          -  Subjects who agree to use effective contraception until 90 days after study drug&#xD;
             administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received any investigational drugs in other clinical or post-marketing studies within&#xD;
             120 days before the study or is scheduled to receive any investigational drugs&#xD;
&#xD;
          -  Donated 400 mL of whole blood within 90 days before the study or during the period&#xD;
             from the screening, 200 mL of whole blood within 30 days, or blood components within&#xD;
             14 days before the study, or is scheduled to donate 400 mL of whole blood or blood&#xD;
             components&#xD;
&#xD;
          -  Received medication within 7 days before hospitalization (Day -2) or is scheduled to&#xD;
             receive medication&#xD;
&#xD;
          -  Received systemic medications influencing immune functions (e.g., steroids, tacrolimus&#xD;
             hydrate, anticancer drugs, and biological products) within 365 days before study drug&#xD;
             administration&#xD;
&#xD;
          -  Received a live virus vaccine (e.g., BCG, polio, measles, and rubella) within 180 days&#xD;
             before study drug administration, or cannot agree not to receive these vaccines for&#xD;
             180 days after study drug administration&#xD;
&#xD;
          -  Received a live virus vaccine (e.g., BCG, polio, measles, and rubella) within 180 days&#xD;
             before study drug administration, or cannot agree not to receive these vaccines for&#xD;
             180 days after study drug administration&#xD;
&#xD;
          -  A deviation from the normal range of blood pressure, pulse rate, body temperature, or&#xD;
             standard 12-lead ECG (see Table 3.3-1) at screening or the day before study drug&#xD;
             administration (Day -1)&#xD;
&#xD;
          -  Any deviation of the normal ranges in laboratory tests before study drug&#xD;
             administration&#xD;
&#xD;
          -  Failure to meet any criteria for standard 12-lead ECG for QT assessment at screening&#xD;
&#xD;
          -  A positive result for tuberculosis test&#xD;
&#xD;
          -  Concurrent or history of drug allergies, anaphylaxis, or severe allergic reaction&#xD;
&#xD;
          -  Upper GI disease&#xD;
&#xD;
          -  Concurrent or previous hepatic disease (e.g., viral hepatitis and drug-induced liver&#xD;
             injury)&#xD;
&#xD;
          -  Concurrent or previous heart disease (e.g., congestive heart failure, angina pectoris,&#xD;
             and arrhythmia requiring treatment)&#xD;
&#xD;
          -  Concurrent or previous respiratory disease (e.g., bronchial asthma and chronic&#xD;
             bronchitis; except for a history of childhood asthma)&#xD;
&#xD;
          -  Previous operation of gut excision&#xD;
&#xD;
          -  Concurrent or previous renal disease (e.g., acute renal failure, glomerulonephritis,&#xD;
             and interstitial nephritis; except for a history of calculus)&#xD;
&#xD;
          -  Concurrent or previous endocrine disease (e.g., hyperthyroid, abnormality of growth&#xD;
             hormone)&#xD;
&#xD;
          -  Concurrent or previous cerebrovascular disorder (e.g., cerebral infarction)&#xD;
&#xD;
          -  Concurrent or previous malignant tumor&#xD;
&#xD;
          -  Concurrent or previous serious infection (e.g., sepsis, pneumonia requiring&#xD;
             hospitalization, and pyelonephritis)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=1089</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>June 30, 2014</last_update_submitted>
  <last_update_submitted_qc>June 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP2408</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

